Browsing Category

66193 posts

Leifras Celebrates 25th Anniversary, Setting Vision for Becoming Global Infrastructure Through "Sports and Social"

Operating Across All 47 Prefectures in Japan, Ranking No. 1 in School…
GeeLark Expands Its AIGC Suite and Opens AI Content Creation to Free Users

GeeLark Expands Its AIGC Suite and Opens AI Content Creation to Free Users

SINGAPORE, Aug. 28, 2026 /PRNewswire/ — GeeLark today announced a major expansion…

Formosa Pharmaceuticals Files Clinical Trial Application for TSY-110, an Antibody-Drug Conjugate Biosimilar Targeting HER2-Positive Breast Cancers

TSY-110 is positioned to become the first biosimilar alternative to Roche’s Kadcyla®…
HiRO and Differentia Biotech Forge Strategic Alliance to Redefine Clinical Trial Design Through AI-Powered Simulation

HiRO and Differentia Biotech Forge Strategic Alliance to Redefine Clinical Trial Design Through AI-Powered Simulation

Memorandum of Understanding establishes a framework for joint development of clinical trial…

Asieris Pharmaceuticals Releases 2026 Semi-Annual Report: Core Product Commercialization Delivers, Entering a Harvest Period as the Company Accelerates Its Transition to Biopharma

SHANGHAI, Aug. 28, 2026 /PRNewswire/ — Asieris Pharmaceuticals today released its 2026…

Kazia Therapeutics Limited Announces Pricing of Up to $120 Million Public Offering

SYDNEY, Aug. 28, 2026 /PRNewswire/ — Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or…

Why Helsinki Should Be on Every Art Lover's Travel List in Summer 2027

HELSINKI, Aug. 28, 2026 /PRNewswire/ — Following a record-breaking edition that attracted more…

InxMed Announces Publication in The Lancet Oncology Featuring Encouraging Antitumor Activity of Ifebemtinib in Combination with Garsorasib in Previously Treated Metastatic Colorectal Cancer (CRC) Harboring KRAS G12C Mutation

NANJING, China, Aug. 28, 2026 /PRNewswire/ — InxMed Co., Ltd ("InxMed"), a…